Processing

Please wait...

Settings

Settings

1. WO2006044732 - 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

Publication Number WO/2006/044732
Publication Date 27.04.2006
International Application No. PCT/US2005/037148
International Filing Date 14.10.2005
Chapter 2 Demand Filed 14.08.2006
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
48
Two nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C07D 239/46 (2006.01)
C07D 409/04 (2006.01)
C07D 413/04 (2006.01)
C07D 403/04 (2006.01)
C07D 401/04 (2006.01)
C07D 405/04 (2006.01)
CPC
A61K 31/50
A61K 31/505
C07D 239/42
C07D 239/46
C07D 239/47
C07D 239/48
Applicants
  • AVENTIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard Bridgewater, NJ 08807-2854, US (AllExceptUS)
  • LIM, Sungtaek [KR/US]; US (UsOnly)
  • HARRIS, Keith, John [GB/US]; US (UsOnly)
  • STEFANY, David [US/US]; US (UsOnly)
  • GARDNER, Charles, J. [US/US]; US (UsOnly)
  • CAO, Bin [CN/US]; US (UsOnly)
  • BOFFEY, Ray [GB/GB]; GB (UsOnly)
  • GILLESPY, Timothy, A. [US/US]; US (UsOnly)
  • AGUIAR, Joacy, C. [BR/US]; US (UsOnly)
  • HUNT, Hazel, J. [GB/GB]; GB (UsOnly)
  • DECHAUX, Elsa, A. [FR/GB]; GB (UsOnly)
Inventors
  • LIM, Sungtaek; US
  • HARRIS, Keith, John; US
  • STEFANY, David; US
  • GARDNER, Charles, J.; US
  • CAO, Bin; US
  • BOFFEY, Ray; GB
  • GILLESPY, Timothy, A.; US
  • AGUIAR, Joacy, C.; US
  • HUNT, Hazel, J.; GB
  • DECHAUX, Elsa, A.; GB
Agents
  • BOLCSAK, James, W. ; SANOFI-AVENTIS U.S. LLC Route #202-206 P.O. Box 6800 Bridgewater, NJ 08807-0800, US
Priority Data
60/619,27215.10.2004US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
(FR) AMINO-PYRIDIMIDINE 2, 6-SUBSTITUEE-4-MONOSUBSTITUEE EN TANT QU'ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2
Abstract
(EN)
The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
(FR)
La présente invention a trait à un composé de formule (I) dans laquelle: Cy1, Cy2, L1, L2 et R1 sont tels que définis dans la description, à une composition pharmaceutique comprenant une quantité pharmaceutiquement efficace d'un ou de plusieurs composés de formule (I) en mélange avec un support pharmaceutiquement acceptable, et à un procédé de traitement d'un patient souffrant d'un trouble médié par la PGD2 comprenant, mais de manière non limitée, une maladie allergique (telle que la rhinite allergique, la conjonctivite allergique, la dermatite atopique, l'asthme et l'allergie alimentaire), la mastocytose systémique, des troubles accompagnés d'activation des mastocytes, le choc anaphylactique, la bronchoconstriction, la bronchite, l'urticaire, l'eczéma, les maladies accompagnées de démangeaison (telles que la dermatite atopique et l'urticaire), des maladies (telles que la cataracte, le décollement de la rétine, l'inflammation, l'infection et les troubles du sommeil) qui sont générées de manière secondaire conséquentes à un comportement accompagné de démangeaison (telles que griffures et battade), l'inflammation, les maladies obstructives respiratoires, la lésion ischémique au retour de la perfusion, l'accident vasculaire cérébral, la polyarthrite rhumatoïde chronique, la pleurésie, la colite ulcéreuse et analogues par l'administration au dit patient d'une quantité pharmaceutiquement efficace d'un composé de formule (I).
Also published as
CO07036912
CRCR2007-009003
DZDZP2007000272
NO20072440
NZ553919
PH12007500803
RU2007117913
US11735751
US11735760
Latest bibliographic data on file with the International Bureau